ArticleEmerging microbes & infections2022
Emergence of colistin-resistant hypervirulent
Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- A systematic review of hypervirulentFrontiers in medicine · 2025Pooled it
- Global prevalence of mutation in theFrontiers in microbiology · 2024Pooled it
- Emergence of carbapenem-resistant putative hypervirulentEmerging microbes & infections · 2026Article
- Molecular Epidemiology ofMicroorganisms · 2026Article
- Molecular analysis of polymyxin B resistance in clinical carbapenem-resistant Klebsiella pneumoniae isolates from a large tertiary care teaching hospital in Southwest China.BMC microbiology · 2026Article
- Carbapenem resistance and hypervirulence iniScience · 2026Review
- Emergence of Carbapenem-Resistant Hypervirulent ST111 K63Polish journal of microbiology · 2026Article
- Pathogenic Characteristics and Molecular Epidemiological Analysis ofInfection and drug resistance · 2026Article
- Clinical Characteristics and Whole-Genome Sequencing Analysis of Carbapenem- and Colistin-Resistant HypervirulentInfection and drug resistance · 2026Article
- Establishment of epidemiological cut-off values of cefotaxime-sulbactam againstFrontiers in microbiology · 2026Article
- β,β-Dimethylacrylalkannin Restores Colistin Efficacy AgainstAntibiotics (Basel, Switzerland) · 2025Article
- A systematic analysis of various clonal lineages of colistin-resistant Klebsiella pneumoniae with mgrB mutations.Molecular biology reports · 2025Review
- Molecular characterization of colistin resistance in carbapenem-resistantMicrobiology spectrum · 2025Article
- A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.Medical microbiology and immunology · 2025Article
- New insights and perspectives on the virulence of hypervirulent Klebsiella pneumoniae.Folia microbiologica · 2025Review
- Risk Factors and Prognosis of Polymyxin- and Carbapenem-Resistant Enterobacteriaceae Infections: A Propensity-Matched Real-World Study.Microorganisms · 2025Article
- Multidrug-resistant hypervirulentFuture microbiology · 2025Review
- Emergence ofMicrobiology spectrum · 2025Article
- Characterization and genome analysis of Klebsiella phages with lytic activity against Klebsiella pneumoniae.Virus genes · 2025Article
- Molecular epidemiology of carbapenem-resistant hypervirulentFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin is regarded as a last-resort agent to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria, especially carbapenem-resistant isolates. In recent years, reports of colistin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.